| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [D. F., K. W. S.]; Weill Graduate School of Medical Sciences of Cornell University, New York, New York 10021 [D. F., B. G., K. W. S.]; and Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [Z. H., E. A. K.]
Ecteinascidin-743 (ET-743) is a promising chemotherapeutic agent currently in Phase III clinical trials. Previous studies indicated a novel spectrum of activity for this agent, including transcriptional inhibition. Initially hypothesized to target a single transcription factor (NF-Y), we now show that ET-743 is a more general inhibitor of activated transcription. Induction of the Sp1-regulated p21 gene by Trichostatin A (TSA) was blocked by ET-743 at concentrations that had minimal effect on uninduced (constitutive) expression. Moreover, ET-743 blocked induction of Gal4 fusion proteins by TSA without affecting activation mediated by the fusion proteins in the absence of the inducer. Finally, microarray analysis of SW620 cells treated with TSA and/or ET-743 indicated that activation of TSA-responsive promoters was blocked by ET-743 with little affect on nonresponsive promoters. These results, taken together with previous reports, leads us to suggest a mechanism whereby ET-743 is a novel, potent, and general inhibitor of activated but not uninduced transcription.
This article has been cited by other articles:
|
|
 |
|
  J. A. Casado, P. Rio, E. Marco, V. Garcia-Hernandez, A. Domingo, L. Perez, J. C. Tercero, J. J. Vaquero, B. Albella, F. Gago, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin Mol. Cancer Ther., May 1, 2008; 7(5): 1309 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Newman, A. D. Bailey, and A. M. Weiner Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling PNAS, June 20, 2006; 103(25): 9613 - 9618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Marco and F. Gago DNA Structural Similarity in the 2:1 Complexes of the Antitumor Drugs Trabectedin (Yondelis) and Chromomycin A3 with an Oligonucleotide Sequence Containing Two Adjacent TGG Binding Sites on Opposing Strands Mol. Pharmacol., December 1, 2005; 68(6): 1559 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Minuzzo, M. Ceribelli, M. Pitarque-Marti, S. Borrelli, E. Erba, A. diSilvio, M. D'Incalci, and R. Mantovani Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters Mol. Pharmacol., November 1, 2005; 68(5): 1496 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fayette, I. R. Coquard, L. Alberti, D. Ranchere, H. Boyle, and J.-Y. Blay ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas Oncologist, November 1, 2005; 10(10): 827 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi, F. Marchesi, C. O. Olimpio, C. Bonardi, A. Garbi, A. Lissoni, et al. Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production Cancer Res., April 1, 2005; 65(7): 2964 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Morioka, L. Weissbach, T. Vogel, G. P. Nielsen, G. T. Faircloth, L. Shao, and F. J. Hornicek Antiangiogenesis Treatment Combined with Chemotherapy Produces Chondrosarcoma Necrosis Clin. Cancer Res., March 1, 2003; 9(3): 1211 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Glaser, M. J. Staver, J. F. Waring, J. Stender, R. G. Ulrich, and S. K. Davidsen Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines Mol. Cancer Ther., February 1, 2003; 2(2): 151 - 163. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
